Brian J Tunquist
Overview
Explore the profile of Brian J Tunquist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pan D, Kaufman J, Htut M, Agrawal M, Mazumder A, Cornell R, et al.
Cancer Med
. 2021 Dec;
11(2):358-370.
PMID: 34921527
Filanesib is a first-in-class kinesin spindle protein inhibitor which demonstrated safety and encouraging activity in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma in a preliminary analysis of dose-escalation...
2.
Shah J, Kaufman J, Zonder J, Cohen A, Bensinger W, Hilder B, et al.
Cancer
. 2017 Aug;
123(23):4617-4630.
PMID: 28817190
Background: Filanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has demonstrated preclinical antimyeloma activity. Methods: This open-label Phase 1/2 study determined the maximum tolerated dose of...
3.
Chari A, Htut M, Zonder J, Fay J, Jakubowiak A, Levy J, et al.
Cancer
. 2016 Jul;
122(21):3327-3335.
PMID: 27433944
Background: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase...
4.
Whiting J, Nygren P, Tunquist B, Langeberg L, Seternes O, Scott J
J Biol Chem
. 2015 Jun;
290(32):19445-57.
PMID: 26088133
The proximity of an enzyme to its substrate can influence rate and magnitude of catalysis. A-kinase anchoring protein 220 (AKAP220) is a multivalent anchoring protein that can sequester a variety...
5.
Tunquist B, Wood K, Walker D
Clin Cancer Res
. 2013 Feb;
19(5):1302.
PMID: 23393075
No abstract available.
6.
Tunquist B, Woessner R, Walker D
Mol Cancer Ther
. 2010 Jun;
9(7):2046-56.
PMID: 20571074
Kinesin spindle protein (KSP/Eg5) inhibitors are novel anticancer agents that have thus far shown only modest activity in the clinic. Understanding how to identify patients who may be most sensitive...
7.
Tunquist B, Hoshi N, Guire E, Zhang F, Mullendorff K, Langeberg L, et al.
Proc Natl Acad Sci U S A
. 2008 Aug;
105(34):12557-62.
PMID: 18711127
A-Kinase Anchoring Proteins (AKAPs) ensure the fidelity of second messenger signaling events by directing protein kinases and phosphatases toward their preferred substrates. AKAP150 brings protein kinase A (PKA), the calcium/calmodulin...
8.
Tunquist B, Eyers P, Chen L, Lewellyn A, Maller J
J Cell Biol
. 2003 Dec;
163(6):1231-42.
PMID: 14691134
In cells containing disrupted spindles, the spindle assembly checkpoint arrests the cell cycle in metaphase. The budding uninhibited by benzimidazole (Bub) 1, mitotic arrest-deficient (Mad) 1, and Mad2 proteins promote...
9.
Ionov Y, Le X, Tunquist B, Sweetenham J, Sachs T, Ryder J, et al.
Anticancer Res
. 2003 Apr;
23(1A):167-78.
PMID: 12680209
Background: The Pim-1 33-kDa protein is a serine/threonine protein kinase that is capable of enhancing the rate of occurrence of c-Myc-induced lymphomas, and functions to block factor-withdrawal and genotoxic stress-induced...
10.